Chugai Pharmaceutical Co., Ltd. Stock OTC Markets
Stocks
CHGCY
US1712691039
Pharmaceuticals
OTC Markets Traded|
Market Closed -
OTC Markets
16:00:00 2026-09-16 EDT
|
5-day change | 1st Jan Change | ||
| 20.54 USD | -1.15% |
|
-1.77% | -21.81% |
| 08-21 | Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets | MT |
| 08-17 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
| Market Cap | 10,606B 68.38B 59.26B 56.01B 50.85B 95.3B 6,560B 95.87B 669B 258B 3,327B 257B 251B | P/E 2026 * |
21x | P/E 2027 * | 18.2x |
|---|---|---|---|---|---|
| Enterprise Value | 9,696B 62.51B 54.17B 51.2B 46.49B 87.12B 5,997B 87.64B 611B 236B 3,042B 235B 230B | EV / Sales 2026 * |
6.98x | EV / Sales 2027 * | 6.18x |
| Free-Float |
38.12% | Yield 2026 * |
2.11% | Yield 2027 * | 2.41% |
| Markets | Quality | ||
|---|---|---|---|
OTC Markets
| CHGCY | Delayed | |
Boerse Muenchen
| CUP0 | Real-time | |
|
Deutsche Boerse AG
| CUP0 | Delayed |
Last Transcript: Chugai Pharmaceutical Co., Ltd.
| 1 day | -1.15% | ||
| 1 week | -1.77% | ||
| Current month | -4.69% | ||
| 1 month | -4.69% | ||
| 3 months | -12.11% | ||
| 6 months | -28.80% | ||
| Current year | -21.81% |
| 1 week | 20 |  | 21.79 |
| 1 month | 20 | | 22.96 |
| Current year | 20 | | 34.84 |
| 1 year | 20 | | 34.84 |
| 3 years | 13.85 | | 34.84 |
| 5 years | 10.99 | | 34.84 |
| 10 years | 4.49 | | 100 |
| Manager | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 63 | 2021-02-28 |
Iwaaki Taniguchi
DFI | Director of Finance/CFO | 59 | 2024-03-27 |
Kazuhiko Nishi
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
BRD | Director/Board Member | 63 | 2020-02-29 |
Iwaaki Taniguchi
BRD | Director/Board Member | 59 | 2024-03-27 |
| Director/Board Member | 51 | 2025-02-28 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.15% | -1.77% | - | - | 68.38B | |
| +0.15% | +1.21% | +48.79% | +97.65% | 1,014B | |
| +0.03% | +0.07% | +51.47% | +65.55% | 644B | |
| -0.20% | +4.62% | +21.39% | +72.57% | 464B | |
| -0.84% | +4.11% | +38.13% | +39.45% | 354B | |
| +0.62% | +2.73% | +19.28% | +25.19% | 265B | |
| +0.80% | +4.26% | +7.57% | +14.27% | 253B | |
| +0.19% | -3.81% | +37.81% | +44.35% | 203B | |
| +0.54% | -3.96% | -25.59% | -57.73% | 186B | |
| +0.94% | +1.39% | +33.21% | +95.16% | 183B | |
| Average | +0.11% | +0.96% | +25.79% | +44.05% | 396.31B | |
| Weighted average by Cap. | +0.11% | +1.41% | +34.23% | +60.24% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1,388B 8.95B 7.76B 7.33B 6.66B 12.47B 859B 12.55B 87.53B 33.82B 436B 33.62B 32.88B | 1,529B 9.86B 8.54B 8.07B 7.33B 13.74B 946B 13.82B 96.39B 37.25B 480B 37.03B 36.21B |
| Net income | 506B 3.26B 2.83B 2.67B 2.43B 4.55B 313B 4.58B 31.92B 12.33B 159B 12.26B 11.99B | 583B 3.76B 3.26B 3.08B 2.8B 5.24B 361B 5.27B 36.78B 14.21B 183B 14.13B 13.82B |
| Net Debt | -910B -5.87B -5.09B -4.81B -4.36B -8.18B -563B -8.23B -57.38B -22.17B -286B -22.04B -21.55B | -1,151B -7.42B -6.43B -6.08B -5.52B -10.34B -712B -10.4B -72.55B -28.04B -361B -27.87B -27.25B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-16 | US$20.54 | -1.15% | 221,870 |
| 26-09-15 | US$20.78 | +0.14% | 907,760 |
| 26-09-14 | US$20.75 | 0.00% | 301,525 |
| 26-09-11 | US$20.75 | +1.17% | 271,743 |
| 26-09-10 | US$20.51 | -1.91% | 321,059 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4519 Stock
- CHGCY Stock
Select your edition
All financial news and data tailored to specific country editions
